Dergiler / Acta Medica / 2021 / Cilt: 52 - Sayı: 2

Investigation of IL-17A, IL-17F, IL-34 Levels of Patient with Multiple Sclerosis and Pseudotumor Cerebri

Sayfa
114–121
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

More extensive studies are needed to determine whether IL-34 can be a marker in the return of the disease from radiologically isolated syndrome to clinical MS.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Multiple Sclerosis is an inflammatory demyelinating disease characterized by lymphocyte infiltration and demyelination of brain tissue and central nervous system.
📊
Temel Bulgular & Veri:Materials and Methods: This study aimed to evaluate the interleukin (IL-17A, IL-17F, and IL-34 cytokine) levels in the cerebrospinal fluid of Relapsing-Remitting Multiple Sclerosis (n=23), radiologically isolated syndrome (n=5) and pseudotumor cerebri (n=15) cases.
💡
Sonuç & Katkı:More extensive studies are needed to determine whether IL-34 can be a marker in the return of the disease from radiologically isolated syndrome to clinical MS.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Objective: Multiple Sclerosis is an inflammatory demyelinating disease characterized by lymphocyte infiltration and demyelination of brain tissue and central nervous system. Materials and Methods: This study aimed to evaluate the interleukin (IL-17A, IL-17F, and IL-34 cytokine) levels in the cerebrospinal fluid of Relapsing-Remitting Multiple Sclerosis (n=23), radiologically isolated syndrome (n=5) and pseudotumor cerebri (n=15) cases. In this study, lumbar puncture cerebrospinal fluid obtained from the patients who were diagnosed with Multiple Sclerosis aged between 21-55. The PTC group included patients with pseudotumor cerebri aged 28-60 years. The levels of IL-17A, IL-17F, IL-34 cytokines were determined by ELISA kit. Results: In this study, Among the studied cytokines in the cerebrospinal fluid samples of the patients, median (min-max) values of IL-17A for the Demyelinated group and pseudotumor cerebri group were 50 (7-257) pg/ml and 2 (1-6) pg/ml respectively, a statistically significant difference (p<0.01) has been observed in between the two groups. Median (minmax) values of IL-17F for the Demyelinated group and pseudotumor cerebri group were 32 (6-891) pg/ml and 2 (1-3) pg/ml respectively, a statistically significant difference (p<0.01) has been observed between the two groups. Median (min-max) values of IL-34 for Demyelinated group and pseudotumor cerebri group were 16 (4-197) pg/ml and 2 (1-11) pg/ml respectively, a statistically significant difference (p<0.01) has been observed in between the two groups (Lower limit for the cytokine values have been determined as IL-17A: 3,93 pg/ml, IL-17F: 2,23 pg/ml, IL-34: 3,12 pg/ml). IL-34, was found to be high in Multiple sclerosis patients. This is important for the cerebral endothelial reaction in Multiple sclerosis. Conclusion: The high levels of IL-34 in cerebrospinal fluid samples suggest that it may be a new treatment strategy and an adjunct cytokine in the diagnosis of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and demyelinating disease. More extensive studies are needed to determine whether IL-34 can be a marker in the return of the disease from radiologically isolated syndrome to clinical MS.

🔖

Bu Makaleye Atıf Yap

ORALLAR, H., KARABÖRK, Ş., TÜRKOĞLU, Ş. A. (2021). Investigation of IL-17A, IL-17F, IL-34 Levels of Patient with Multiple Sclerosis and Pseudotumor Cerebri. Acta Medica, Cilt: 52 - Sayı: 2, 114–121. https://ajindex.com/articles/406495

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (17)

  1. Compston A, Coles A. Multiple sclerosis. Lancet (London, England). 2008; 372(9648): 1502–1517
  2. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018; 17(2): 162–173
  3. Bjartmar C, Trapp BD. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol. 2001; 14(3): 271–278
  4. Okuda DT, Mowry EM, Beheshtian A, et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology. 2009; 72(9): 800–805
  5. Andersson M, Alvarez-Cermeño J, Bernardi G, et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry.1994; 57(8): 897–902
  6. Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015; 15(9): 545–558
  7. Dargahi N, Katsara M, Tselios T, et al. Multiple Sclerosis: Immunopathology and Treatment Update. Brain Sci. 2017; 7(7): 78
  8. Van Oosten BW, Lai M, Hodgkinson S, et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebocontrolled, MR-monitored phase II trial. Neurology.1997; 49(2): 351–357
  9. Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015; 14(2): 183–193
  10. Van Langelaar J, Van der Vuurst de Vries RM, Janssen M, et al. T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early intervention. Brain. 2018; 141(5): 1334–1349
  11. Stromnes IM, Cerretti LM, Liggitt D, et al. Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. Nat Med. 2008; 14(3): 337–342
  12. Baghdadi M, Umeyama Y, Hama N, et al. Interleukin‐34, a comprehensive review. J Leukoc Biol. 2018; 104(5): 931-51
  13. Sospedra, M, Martin, R. Immunology of Multiple Sclerosis. Semin Neurol. 2016; 36(2): 115–127
  14. Truong AD, Hong Y, Lee J, et al. Interleukin-34 Regulates Th1 and Th17 Cytokine Production by Activating Multiple Signaling Pathways through CSF-1R in Chicken Cell Lines. Int J Mol Sci. 2018; 19(6): 1665
  15. Portelli M, Papageorgiou PN. An update on idiopathic intracranial hypertension. Acta Neurochir (Wien). 2017; 159(3): 491–499
  16. Friedman DI. The pseudotumor cerebri syndrome. Neurol Clin. 2014; 32(2): 363–396
  17. Matejčíková Z, Mareš J, Sládková V, et al. Cerebrospinal fluid and